Autolus Therapeutics plc Long-Term Debt | AUTL

Long-term debt is a financial obligation of a company or an individual with a repayment period exceeding one year from the date it arises. In accounting, such obligations are recorded under the "long-term liabilities" section.

Main characteristics:

Term exceeds 12 months
Can take the form of bonds, bank loans, credit lines, leasing, or loans from affiliated parties
Repaid through regular payments (interest and/or principal) over several years

Why long-term debt is needed:

Investment in development
Allows financing of large projects — new factories, production lines, innovative developments — without diverting working capital.
Smoothing of cash flows
A long-term payment schedule facilitates budget planning and reduces short-term financial risks.
Optimization of capital structure
A combination of equity and borrowed capital can reduce the average cost of business financing.

A high level of long-term debt may indicate that a company heavily relies on borrowed funds. This increases risks, especially in conditions of rising interest rates or declining profits. However, a moderate level of debt can signal a sound growth strategy — for example, the company takes a loan to expand its business.

If a company uses borrowed funds effectively (e.g., invests in profitable projects), this can lead to profit growth and, consequently, an increase in stock value. An investor evaluates whether the investments made using debt are paying off.

It is important to monitor whether the company can regularly pay interest and repay the principal. Payment difficulties can lead to reduced dividends, a drop in stock value, and even bankruptcy.

Examples of long-term debt:

Mortgage loans for property purchases
Corporate bonds issued by a company to raise capital
Project financing — long-term loans for building or expanding production facilities
Leasing obligations for equipment or transport

Annual Long-Term Debt Autolus Therapeutics plc

2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
66.8 M	49.6 M	47.9 M	19.2 M	-	-	-	285 K	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
66.8 M	285 K	36.8 M

Quarterly Long-Term Debt Autolus Therapeutics plc

2026-Q2	2026-Q1	2025-Q4	2025-Q3	2025-Q2	2025-Q1	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
66.8 M	76.9 M	49.6 M	61 M	61.3 M	54.7 M	47.9 M	48.7 M	45.8 M	46.5 M	15.1 M	47 M	-	-	-	-	-	-	16.5 M	-	-	19.6 M	50.6 M	49.5 M	24.3 M	24.1 M	-	30 K	121 K	-	285 K	380 K	-	-	-	763 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
76.9 M	30 K	35.1 M

Long-Term Debt of other stocks in the Biotechnology industry

Issuer	Long-Term Debt	Price	% 24h	Market Cap	Country
Aclaris Therapeutics ACRS	1.56 M	$ 5.71	7.24 %	$ 700 M	USA
Фармсинтез LIFE	13.2 M	-	-	-	Russia
AbbVie ABBV	64.5 B	$ 261.51	1.66 %	$ 463 B	USA
AbCellera Biologics ABCL	137 M	$ 11.09	1.84 %	$ 3.31 B	Canada
Agenus AGEN	30.5 M	$ 7.16	3.17 %	$ 213 M	USA
Ayala Pharmaceuticals AYLA	1.33 M	-	-	$ 7.46 M	Israel
Amryt Pharma plc AMYT	4.05 M	-	-	$ 621 M	Britain
Evelo Biosciences EVLO	43.6 M	-	-14.46 %	$ 27.9 M	USA
ASLAN Pharmaceuticals Limited ASLN	281 K	-	-14.27 %	$ 1.7 M	Singapore
Acorda Therapeutics ACOR	167 M	-	-24.86 %	$ 820 K	USA
Adaptimmune Therapeutics plc ADAP	50.2 M	-	-15.15 %	$ 60.3 M	Britain
Advaxis ADXS	8.14 M	-	-9.65 %	$ 45.9 M	USA
Abeona Therapeutics ABEO	7.81 M	$ 5.39	0.28 %	$ 285 M	USA
Agios Pharmaceuticals AGIO	21.8 M	$ 33.38	0.16 %	$ 1.94 B	USA
Adagene ADAG	1.14 M	$ 3.29	2.94 %	$ 194 M	China
iTeos Therapeutics ITOS	3.76 M	-	-	$ 411 M	USA
Galmed Pharmaceuticals Ltd. GLMD	44 K	$ 4.63	21.05 %	$ 20 M	Israel
Adaptive Biotechnologies Corporation ADPT	127 M	$ 24.82	2.56 %	$ 3.77 B	USA
Akouos AKUS	28.3 M	-	0.23 %	$ 488 M	USA
Albireo Pharma ALBO	10.8 M	-	-0.23 %	$ 916 M	USA
BioXcel Therapeutics BTAI	84.7 M	$ 0.07	9.81 %	$ 855 K	USA
Allakos ALLK	38.2 M	-	-	$ 28.6 M	USA
MediWound Ltd. MDWD	2.01 M	$ 13.84	5.57 %	$ 377 M	Israel
Allena Pharmaceuticals ALNA	210 K	-	3.16 %	$ 1.9 M	USA
Alpine Immune Sciences ALPN	9 M	-	-	$ 2.17 B	USA
Arbutus Biopharma Corporation ABUS	806 K	$ 5.12	0.1 %	$ 981 M	Canada
ADC Therapeutics SA ADCT	1.03 M	$ 1.11	3.76 %	$ 141 M	Schweiz
Ampio Pharmaceuticals AMPE	274 K	-	-11.43 %	$ 502 K	USA
Aridis Pharmaceuticals ARDS	1.29 M	-	17.91 %	$ 11.1 M	USA
Adial Pharmaceuticals ADIL	151 K	$ 4.97	1.43 %	$ 3.32 M	USA
ACADIA Pharmaceuticals ACAD	40.6 M	$ 27.48	0.04 %	$ 4.63 B	USA
AIM ImmunoTech AIM	927 K	$ 0.22	0.05 %	$ 356 K	USA
ADMA Biologics ADMA	69.3 M	$ 9.15	0.16 %	$ 2.18 B	USA
Axcella Health AXLA	25.1 M	-	-16.42 %	$ 249 M	USA
SQZ Biotechnologies Company SQZ	20.9 M	-	57.95 %	$ 12.8 M	USA
Atreca BCEL	60.3 M	-	-11.76 %	$ 5.79 M	USA
Berkeley Lights BLI	22.7 M	-	-7.31 %	$ 87 M	USA
Bellerophon Therapeutics BLPH	203 K	-	-74.18 %	$ 955 K	USA
Achieve Life Sciences ACHV	11.2 M	$ 7.28	3.12 %	$ 317 M	USA
Baudax Bio BXRX	1.52 M	-	0.59 %	$ 63 K	USA
Calithera Biosciences CALA	136 K	-	-10.95 %	$ 876 K	USA
CymaBay Therapeutics CBAY	467 K	-	-	$ 3.45 B	USA
Codiak BioSciences CDAK	34.9 M	-	-55.98 %	$ 2.15 M	USA
ChemoCentryx CCXI	4.72 M	-	-	$ 3.74 B	USA
Akebia Therapeutics AKBA	48.2 M	$ 0.98	3.01 %	$ 252 M	USA
Avid Bioservices CDMO	54.2 M	-	-	$ 789 M	USA
Cerevel Therapeutics Holdings CERE	380 M	-	-	$ 7.29 B	USA
AC Immune SA ACIU	3.69 M	$ 2.67	2.6 %	$ 269 M	Schweiz
Alector ALEC	9.32 M	$ 2.22	3.74 %	$ 229 M	USA